zuclopenthixol decanoate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
zuclopenthixol decanoate: clinical details
Prescribing considerations
- Confirm the decanoate depot product; do not confuse it with short-acting zuclopenthixol acetate.
- Establish previous antipsychotic response and tolerability before prolonged depot exposure.
- Review cardiac, neurological, hepatic, renal, respiratory, endocrine and thromboembolic risk factors.
- Use extra caution in frail older adults, who are more susceptible to sedation, hypotension, confusion and temperature disturbance.
- Avoid routine antipsychotic polypharmacy and review interacting medicines, particularly QT-prolonging or myelosuppressive agents.
Contraindications and cautions
- Hypersensitivity to zuclopenthixol decanoate or an excipient.
- Circulatory collapse.
- Depressed consciousness from any cause, including alcohol, barbiturate or opioid intoxication.
- Coma.
Monitoring
- Clinical response, relapse symptoms and adverse effects after injections.
- Extrapyramidal symptoms, akathisia and tardive dyskinesia.
- Sedation, postural symptoms, weight and metabolic risk, including glucose control where relevant.
- Pulse, ECG and electrolytes when cardiac or QT-risk factors are present.
- Blood-cell abnormalities when clinically indicated, especially with infection symptoms or myelosuppressive treatment.
- Liver function and serum zuclopenthixol concentrations where hepatic impairment makes this appropriate.
- Prolactin-related, sexual and reproductive adverse effects.
- Venous-thromboembolism risk before and during treatment.
Clinical pharmacology
Zuclopenthixol is a dopamine D1/D2 receptor antagonist with alpha-adrenergic, serotonergic and slight antihistaminic activity. Following deep intramuscular administration, active zuclopenthixol is released gradually from the decanoate depot.
Formulation and product differences
- Clopixol Injection is supplied as a 200 mg/mL oily solution in ampoules and a multidose vial presentation.
- Clopixol Conc. Injection is a 500 mg/mL concentrated oily solution supplied in ampoules.
- Both contain thin vegetable oil and must not be confused with zuclopenthixol acetate injection.
- They may be mixed in one syringe with products in the Clopixol injection range but not with other injection fluids.
zuclopenthixol decanoate interactions
Tell the prescriber about all medicines, including non-prescription products. Important examples include:
Alcohol, barbiturates and other sedatives
Sedation and impairment may be increased.
QT-prolonging medicines, including some antiarrhythmics, antibiotics, antihistamines and antipsychotics
Combined use can increase the risk of serious abnormal heart rhythms and should generally be avoided.
Lithium
Combined treatment may increase neurotoxicity and cardiac risk.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.